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BACKGROUND: The costs of interferon beta are high
(£10,000/patient year). The impact on health status and
quality of life is uncertain. These factors, plus limited
funding, restrictive indications and guidance for use
mean prescribing in the UK is low and variable. To ad-
dress these issues, a trial of interferon beta was proposed.
The research costs of the trial were substantial (£10.3
million). The treatment and support costs of the trial
could be in the region of £75 million. OBJECTIVES: To
assess the potential impact of the trial on the costs and
benefits of treatment for people with multiple sclerosis
(MS). METHODS: The evaluation compared the poten-
tial use, costs and QALYs of interferon beta, azathio-
prine and usual care with and without the trial. Decision
analysis was used to estimate the expected costs and
quality adjusted life years (QALYs) in two situations
with the trial: (i) the treatment with the highest QALY is
used; (ii) treatment decisions are made on efficiency crite-
ria (expected costs and QALYs). RESULTS: If treatment
decisions were made to maximise QALYs, the expected
cost and QALYs of the trial were between £3,026,000,000
and £3,904,000,000 and between 5,551 and 14,012 re-
spectively. The expected cost/QALY gained was between
£0–£369,000. Treatment decisions made on efficiency
criteria were associated with expected costs and QALYs
of between £8,292,000,000 and £167,000,000 and be-
tween 5355 and 14,969 respectively. The expected
cost/QALY lost was between £0–£662,728. CONCLU-
SIONS: The expected value of the trial depends upon the
decision-making criteria used and impact of the trial on
treatment decisions. If the trial leads to adoption of treat-
ments with a net cost/QALY less than £100,000, it
would lead to long term savings in the costs of care, but
losses of 251–5355 QALYs in the MS population.
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Cigarette smoking is a known cause of morbidity and
mortality and is associated with 400,000 deaths in the
United States annually. The guidelines released by the
Agency for Health Care Policy and Research (AHCPR)
encourages all clinicians to promote smoking cessation.
OBJECTIVES: To determine cigarette smokers’ knowl-
edge and use of smoking cessation aides and determine if
health care professionals have encouraged patients to
quit smoking cigarettes. METHODS: A survey instru-
ment was mailed in April 1999 with two reminder mail-
ings to 204 adult patients with a diagnosis of tobacco
abuse (ICD-9 code 305.1) in a Medicaid claims database.
RESULTS: Seventy-one of the 181 (39%) deliverable sur-
veys were returned. Seventy-three percent of the respon-
dents started smoking cigarettes at an age less than 18.
Fifty-nine percent of the patients have quit smoking at
least once, but 63% of the patients are currently smok-
ing. The majority of the patients who have quit at least
once (51%) did not use the assistance of smoking cessa-
tion medication. When the patients were asked regarding
who had asked them about their smoking habits, 72%
responded a physician had asked them, 48% responded a
health care professional besides a pharmacist, while only
17% responded that a pharmacist had asked them about
their smoking habits. CONCLUSIONS: Based on the re-
sults of this survey, many cigarette smokers start at a
young age. Additional societal education is needed re-
garding the risks of smoking and smoking cessation
methods. Furthermore, pharmacists need to be more in-
volved in promoting smoking cessation.
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The ultimate goal of pharmaceutical care is to improve
patient’s quality of life (QOL) by maximizing the benefits
and limiting the risks associated with medication ther-
apy. OBJECTIVE: To examine changes in QOL scores
for Veteran patients receiving pharmaceutical care from
clinical pharmacists. METHODS: This study was a pro-
spective multi-site randomized controlled trial of ambula-
tory care clinical pharmacists’ interventions for Veterans
Affairs patients who were at high-risk for drug-related
problems. Health related quality of life was assessed via
the short form 36-item (SF-36) questionnaire. The SF-36
questionnaire was administered to patients in treatment
and control groups at enrollment, 6 and 12 months. Con-
trol patients received usual medical care and intervention
patients were assigned to clinical pharmacists for consul-
tation and follow-up care. RESULTS: A total of 1054 pa-
tients were enrolled from 9 sites, 523 were randomized to
the intervention group and 531 to the control group.
Nine hundred fifty patients completed 6-month question-
naires and 931 completed the study. Clinical pharmacists
had 1855 contacts with intervention patients. The mean
number of contacts was 3.5  2.3. The group time inter-
action term was significant for the general health percep-
tions (GHP) and vitality domains. The average GHP
score declined 1.7 units for intervention patients com-
pared to 5.1 units for control patients (P  0.0066). Vi-
tality scores declined 1.3 units for intervention and 4.2
units for control patients (P  0.0034). CONCLU-
SIONS: The findings indicate ambulatory clinical phar-
macists had a statistical, but not clinically meaningful, ef-
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fect on HRQOL for patients at high-risk for drug-related
problems.
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OBJECTIVES: To gain an understanding of quality mea-
surement as it relates to effectiveness for the delivery of
health services across ambulatory and inpatient sites of
care. The goal is to measure quality through process con-
trol where quality reduction is signaled by departures
from the intended course of treatment. METHODS:
Eighteen months of encounter and claims data covering
over two million lives were assembled into episodes of
care (EOCs) that group together all of the services used
to treat a patient in a clinically homogeneous group de-
fined by intention to treat. EOCs were characterized by a
set of intensity measures (physician RVUs, resource utili-
zation, and costs) and encounter types (hospitalizations,
readmissions, ER visits, etc). Controlling for patient risk,
using multiple regression analysis of demographic and
clinical factors, the dimensions of the care process were
combined into a multivariate performance measure that
recognizes treatment hierarchies and the trade-offs be-
tween prevention and rework. Validation was by strati-
fied sample consistency tests. RESULTS: Treatment in-
tensity and duration measures for EOCs are highly
variable across patients within a given Common Treat-
ment Category, even after controlling for patient risk;
and they are not highly correlated with each other, indi-
cating substantial variation in practice patterns. Multi-
variate performance measures, based on trade-offs be-
tween prevention and rework, identified episode groupings
with statistically significant departures from norms. Vali-
dations showed robust clustering of practice patterns
around the incidence of rework. CONCLUSIONS: A
useful quality indicator can be tailored to the specific cir-
cumstances of care by grouping episodes of care by treat-
ment type and by accounting for the characteristics of the
patient. EOC grouping, when risk adjusted, can be used
to assess the effectiveness of health care by identifying
practices that deviate significantly from norms.
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The deleterious effects of non-compliance have been well
documented. OBJECTIVES: To determine compliance
and persistence with initial therapy at 6 and 12 month in-
tervals for twice daily and once daily (XR) medication
regimens using glipizide and venlafaxine. METHODS: A
retrospective database review identified newly treated Di-
abetes and Depression patients. Filled prescriptions served
as a proxy for compliance and persistency. Continuous
eligibility was required. Patients on greater than twice
daily regimen were excluded. Patients with a gap of 2.5X
days supply were deemed non-persistent implying a toler-
ance level of compliance down to 40%. A two-sample
student’s t-test was performed at the 6 and 12 month in-
terval to detect statistical significance. Evaluable patients
at 6 months for glipizide qd was 13,580 while 287 twice
daily glipizide patients were identified. Evaluable patients
for the venlafaxine comparison at 6 months was 2,412
for the once daily formulation and 616 for the twice daily
formulation. RESULTS: The glipizide once daily group
exhibited higher compliancy at the 6th (13% higher, P 
0.01) and 12th (20% higher, P  0.01) month interval
versus glipizide twice daily. The glipizide once daily
group had a 37% higher (P  0.01) persistency rate at 12
months vs the twice daily group. Venlafaxine once daily
improved compliance by 14% at 6 months, and 11% at
12 months while persistency was 6% higher at 12
months for the once daily group. CONCLUSIONS: Sim-
plifying regimen complexity from twice a day to once a
day yields substantial benefits for compliance, persis-
tency, and ultimately, should positively impact efficacy
rates.
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